To ensure compliance with the EC Grant Agreement and Consortium Agreement, and to ensure that the projects agreed deliverables and milestones are achieved within budget, and on time. To this end, strict procedures have been installed and officialised in a Project Management Manual. Procedures entail production and dissemination of project documentation, meetings, achievement of milestones and deliverables and the budget
To ensure the effective inter-WP alignment of activities and promote efficient and effective internal communication and decision-making
To develop a feasible business plan for the sustainable continuation of the operational infrastructures and processes needed to continue the VALUE-Dx activities well beyond the projects 4-years, and to widen the applicability of study findings beyond the current priority of CA-ARTI in community care settings
https://www.value-dx.eu/wp-content/uploads/2019/07/shutterstock_1030079398.jpg40006000Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-04-21 09:36:392021-04-21 09:36:39VALUE-Dx investigates HTA, Reimbursement and Pricing of Diagnostic Tests for CA-ARTI
https://www.value-dx.eu/wp-content/uploads/2021/04/Stethoscope-and-laptop-scaled.jpg17072560Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-04-01 08:19:092021-04-01 08:20:35Funding models and health economics of diagnostics
https://www.value-dx.eu/wp-content/uploads/2020/06/Antibiotic-pills-Hand-Converted.jpg24822481Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-03-31 07:17:282021-03-31 07:18:42Enhancing the quality of antibiotic prescribing for CA-ARTI in Emergency Rooms through ADEQUATE trial
https://www.value-dx.eu/wp-content/uploads/2019/07/shutterstock_457866949.jpg38405760Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-03-30 13:23:232021-04-01 07:34:54PRUDENCE trial will start in the summer of 2021
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.